WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009065232) CANCER DIAGNOSTIC AND THERAPEUTIC METHODS THAT TARGET PLK4/SAK
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/065232    International Application No.:    PCT/CA2008/002087
Publication Date: 28.05.2009 International Filing Date: 20.11.2008
IPC:
A61K 31/553 (2006.01), A61K 31/404 (2006.01), A61K 31/427 (2006.01), A61K 31/437 (2006.01), A61K 31/44 (2006.01), A61K 31/4439 (2006.01), A61K 31/506 (2006.01), A61K 31/519 (2006.01), A61K 31/551 (2006.01), A61K 31/7105 (2006.01), A61K 48/00 (2006.01), A61P 35/00 (2006.01), A61P 35/04 (2006.01), G01N 33/573 (2006.01), G01N 33/574 (2006.01), G01N 33/68 (2006.01)
Applicants: UNIVERSITY HEALTH NETWORK [CA/CA]; 190 Elizabeth Street, Toronto, ON M5G 2C4 (CA) (For All Designated States Except US).
PAN, Guohua [CA/CA]; (CA) (For US Only)
Inventors: PAN, Guohua; (CA)
Agent: ERRATT, Judy, A.; Gowling Lafleur Henderson LLP, 160 Elgin Street, suite 2600, Ottawa, Ontario K1P 1C3 (CA)
Priority Data:
61/003,825 20.11.2007 US
Title (EN) CANCER DIAGNOSTIC AND THERAPEUTIC METHODS THAT TARGET PLK4/SAK
(FR) PROCÉDÉS DE DIAGNOSTIC ET DE THÉRAPIE DU CANCER QUI CIBLENT PLK4/SAK
Abstract: front page image
(EN)Methods of assessing expression of PLK4 in a cancer patient for use in determining if the patient is a candidate for PLK4antagomst therapy, predicting cancer metastasis and if the patient is a candidate for aggressive cancer therapy. Also provided is the use of PLK4 antagonists in the treatment of cancer and metastasis. Preferred cancers for treatment are breast cancer (basal sub-type and luminal B sub-type) and soft tissue cancers.
(FR)L'invention porte sur des procédés d'évaluation de l'expression de PLK4, chez un patient atteint d'un cancer, qui sont à utiliser pour déterminer si le patient est un candidat pour une thérapie par antagoniste de PLK4, pour prédire une métastase du cancer et si le patient est un candidat pour une thérapie du cancer agressive. L'invention propose également l'utilisation d'antagonistes de PLK4 dans le traitement du cancer et d'une métastase. Les cancers préférés pour le traitement sont le cancer du sein (sous-type basal et sous-type luminal B) et les cancers de tissu mou.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)